HUDDINGE, Sweden Stockholm--(BUSINESS WIRE)-- Medivir AB (Nasdaq Stockholm: MVIR) today announces a new discovery project for a cancer indication, a liver targeted nucleotide prodrug for the treatment of hepatocellular carcinoma (HCC). The project is based on the company’s expertise in nucleoside and nucleotide science and is the first cancer project to emerge from its in-house discovery efforts in oncology that were announced in 2014.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
